Promedior Inc. a biotechnology company focused on advancing new therapeutics to address treatment for fibrosis, recently announced that Olga Pozdynakova of Brigham and Women’s Hospital Boston will be presenting further data on the firm’s ongoing Phase 2 clinical trial of experimental idiopathic pulmonary fibrosis therapy PRM-151, as a possible treatment for myelofibrosis. The results will be presented in a poster session at the 20th Congress of the European Hematology Association (EHA) to be held in Vienna Austria between June 11 and 14, 2015. The presentation will feature results from a 36-week trial in individuals with myelofibrosis and will discuss top clinical measures of the efficacy related to myelofibrosis with a particular focus on validating the PRM-151’s capacity to reduce fibrosis of the bone marrow.
With a new mechanism of action designed to prevent and reverse fibrosis, PRM-151 can address the crucial fibrotic pathology in fibrotic diseases, including myelofibrosis. Promedior’s Phase 2 clinical trial is a 2 stage, multi-center, adaptive design study to assess the safety and efficacy of PRM-151 as a single agent or in joined with a stable dose of ruxolitinib in individuals with Primary Myelofibrosis (PMF) Post-Polycythemia Vera MF (post-PV MF) or Post-Essential Thrombocythemia MF (post-ET MF).
Myelofibrosis is a severe cancer characterized by fibrosis of the bone marrow. It affects almost 18,000 individuals each year in the United States with median age of 61 to 66. The only treatment that might cure is allogeneic bone marrow transplant.
PRM-151 is an endogenous protein that regulates macrophages and monocytes in damaged tissue to prevent and also reverse fibrosis. It has shown anti-fibrotic activity in several pre-clinical fibrotic disease models such as pulmonary fibrosis, chronic nephropathy liver fibrosis and age-related macular degeneration.
A Phase 1b study in individuals suffering with idiopathic pulmonary fibrosis (IPF) has also showed promising results in exploratory efficacy endpoints presented at the 2013 Annual Meeting of the American Thoracic Society. These new results in treating myelofibrosis contribute to a growing body of evidence that the drug could eventually be approved to treat several fibrosis diseases, including IPF.
Read More Recent News
KaloBios Pharmaceuticals, Inc. announced that its potential treatment for Pseudomonas aeruginosa (Pa) lung infections was unable to meet the primary endpoint — “increased time to need for antibiotics for worsening respiratory tract signs and symptoms” — which when achieved indicates a decrease in the risk of developing pulmonary exacerbations. The company is evaluating KB001-A in cystic fibrosis (CF) patients, and these were the first results from its recent phase 2 study.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?